U.S. House panel intensifies scrutiny of Morgan Stanley over IPO linked to Uyghur forced-labor entity. | Three foreign carmakers obtain approval to deploy AI chatbots in cars in China. | Indonesia considers issuing renminbi-denominated bonds amid China’s push against dollarization.
Forced tech transfers are a possible precondition for Chinese firms in Europe. | China closes unclarified aspects of the cross-border data transfer regime. | Over RMB 11 million in penalties signal banking regulators’ focus on data security and risk control.
U.S. export controls extended to subsidiaries of Chinese companies | PBOC broadens foreign access to its bond market by aligning China’s repo framework with global standards | U.S. court rules that DJI failed to counter proof of its military links.
Meihua Liang and Yuting Chen of Commerce & Finance Law Offices present an analysis of China's distinct regulatory model governing digital assets, and its legal implications for market participants
Eric (Ye) Zou of Merits & Tree Law Offices gives an overview of the core elements and key significance of a new pilot scheme which maps out a new way for foreign investors to access China’s flourishing financial markets
The first commercial AI application case in Zhejiang province defines legal limits on generative tools; CFIUS blocked more transactions last year than in previous years amid rising China tensions; and Fintech companies rush to raise equity for stablecoin activity in Hong Kong.
Trump signs memorandum to restrict investments that do not serve American interests; A Jiangsu court ruled that investments in overseas crypto projects are not protected under Chinese law; and Chinese companies raise funds in hope of easing of regulations against private enterprises
Simon Leung, Partner of Baker McKenzie, and Terry Xu, Senior Counsel at FenXun Partners, examine key regulatory shifts in 2024 and provide an outlook of potential regulatory trends for the banking and finance sector in 2025
Calvin Klein parent PVH investigated by Chinese government after pulling out of Xinjiang; Chinese biotech firms targeted by U.S. BIOSECURE Act seek to sell U.S. subsidiaries; and China promises to protect private business while maintaining the existing economic order is still important.
